

RD General Agenda Topics – April 6, 2021

Briefings for Michal

- PRIA/registration overview 2/23rd (complete)
- Dicamba 2/18th (complete)
- Sulfoxaflor 3/4th (complete)
- Pet incidents 3/31st (complete)
- FDA/EPA jurisdiction 4/12th
- Antibiotics – TBD

New Active Ingredients (include original PRIA date)

- Tetraniliprole – completed!
- Broflanilide – completed!
- Fluindapyr – PD signed. PRIA Date **3/5/21** (Original PRIA date 5/29/20) (FB)
- Trifludimoxazin – PD signed. PRIA date **4/21/21** (Original PRIA date 10/16/2020) (FHB) – FD with RD-IO for review
- Picarbutrazox – completed!
- Fluxametamide – completed!
- L-Glufosinate Ammonium – Risk Assessment phase. PRIA date 10/12/2021. ESA issue. Any feedback?

Other Chemical Actions

- Dicamba (Dan K)
 - Fexapan (Corteva) – 100% repack; approved
 - Bayer and BASF requesting feedback on pending pre-mixes
 - Bayer meeting scheduled next week
 - Team is working on OCSPP one pager to propose strategy
 - **24 (c)s** –
 - NC – denial 3/15th
 - GA has resubmitted – no cutoff date, reduced buffer distances
 - TN submissions – asking for soybean cutoff date of 7/30th (to match cotton)
 - **Disapproval notice for TN signed 3/31st; Disapproval 4/11th or withdraw**
 - **Disapproval notice for GA NLT 4/16th**
- Antibiotics – will need to brief the new team (Cynthia)
 - Oxytet – cherry; public process (perhaps not needed)
 - Consultation with partners – Kasugamycin (almond, peach, apricot)
- Cyclaniliprole/flonicamid – first residential use; public process; teams are addressing RD IO comments; OPP-IO comments with the team; completed!
- **Seresto** – pet collar with high rate of incidents (death and neuro); planning a briefing on pet products and incidents; press inquiries; 6a2 reporting
 - **Met with Elanco** – discussed data and labeling; drafting 6a2 letter. Follow up meeting today.
- Imidicloprid – Hemlock – MI – S18 or 24c? Policy on neonic? Discussed with Ed 3/30th

- **Enlist** – Extension of the registration (expires end of 2021); Corteva is looking for a decision to inform seed purchase for soybeans; OGC advises an to update ESA finding

Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction – follow up briefing for Ed 3/10th – RD sent an email for Soloman; anything else needed?
- COVID-19 Activities – Sect 18s –
 - SW2 – follow up from Michal briefing; data potentially supports revoking the S18; team is working on options paper; getting OECA comments

Ex. 5 Deliberative Process (DP)

- Ionopure Air
 - Acteev Facemasks
- OIG Audits
 - Expecting draft dicamba report next week; next steps?
- **PFAS** – RD working with Clark on submissions

Ex. 5 Deliberative Process (DP)

- Inerts meeting with CLA – waiting on additional information from CLA
- FLS/FLAG: debuted Performance Management Toolkit for Federal Supervisors last week; interest from other AA/Regional FLAG reps in sharing it with their supervisors
- 24c for cannibas – J. Housenger letter; OPP position?

Business/process/technology

- ISB – FEP/21-day backlog:
 - backlog addressed by end of April; RD SWAT team addressing newer receipts
 - **Michal feedback on expediting all covid actions? Any updates?**
- eCSF/OPPEL – OPP priority? – ITRMD report May soft launch; requesting time at an OPP staff meeting

Speaking Engagements –

Ex. 5 Deliberative Process (DP)

- IVB3/HB – talent hub (Meredith and Dan retirements) – selecting Dee Colby and Ricardo Jones (IVB3) and Kelly Tindall and Lindsay Roe (HB); other candidates Monica Wait, Debra Rate, Kesha Forrest – announcing today
- FHB/PM position – will need to advertise separately from FHB
- Additional senior vacancies pending discussion with AD – IVB2/PM; FHB/SRS
- FTE discussion (any updates?)
- Developing PMF process proposal with OPP Recruitment and Hiring Workgroup
- OPP Town hall – what is being rolled out? Expectations for division-level EVS; resource implications?

CA topics (Karen Morrison):

- Missing environmental hazard statements (examples?) – RD BC's are generating a response